Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Axel Bellotti"'
Autor:
Caroline Spertini, Alexandre P. Bénéchet, Flora Birch, Axel Bellotti, Mónica Román-Trufero, Caroline Arber, Holger W. Auner, Robert A. Mitchell, Olivier Spertini, Tatiana Smirnova
Publikováno v:
Cell Death Discovery, Vol 10, Iss 1, Pp 1-12 (2024)
Abstract The malignant microenvironment plays a major role in the development of resistance to therapies and the occurrence of relapses in acute myeloid leukemia (AML). We previously showed that interactions of AML blasts with bone marrow macrophages
Externí odkaz:
https://doaj.org/article/2bb2be5d25b741e1bc1d4072669c0f38
Autor:
Oussama ElMokh, Saki Matsumoto, Paulina Biniecka, Axel Bellotti, Karin Schaeuble, Francesco Piacente, Hector Gallart-Ayala, Julijana Ivanisevic, Ivan Stamenkovic, Alessio Nencioni, Aimable Nahimana, Michel A. Duchosal
Publikováno v:
Cell Death and Disease, Vol 13, Iss 4, Pp 1-9 (2022)
Externí odkaz:
https://doaj.org/article/f655c81b71b94683b6b1d9755f5a5853
Autor:
Ioanna Keklikoglou, Ece Kadioglu, Stefan Bissinger, Benoît Langlois, Axel Bellotti, Gertraud Orend, Carola H. Ries, Michele De Palma
Publikováno v:
Cell Reports, Vol 22, Iss 10, Pp 2530-2540 (2018)
Summary: Resistance to antiangiogenic drugs limits their applicability in cancer therapy. Here, we show that revascularization and progression of pancreatic neuroendocrine tumors (PNETs) under extended vascular-endothelial growth factor A (VEGFA) blo
Externí odkaz:
https://doaj.org/article/29a95bd83ae14772b54e6c822e55dbdb
Autor:
Jian-Fei Bai, Somi Reddy Majjigapu, Bernard Sordat, Sophie Poty, Pierre Vogel, Pilar Elías-Rodríguez, Antonio J. Moreno-Vargas, Ana T. Carmona, Irene Caffa, Moustafa Ghanem, Amr Khalifa, Fiammetta Monacelli, Michele Cea, Inmaculada Robina, Consuelo Gajate, Faustino Mollinedo, Axel Bellotti, Aimable Nahimana, Michel Duchosal, Alessio Nencioni
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
11 p.- 2 fig.-4 tab.-8 schem.-1 graph. abst.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases for which chemotherapy has not been very successful yet. FK866 ((E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acry
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases for which chemotherapy has not been very successful yet. FK866 ((E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acry
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c4ff75c600149bbef14b882ef0bbb10
http://hdl.handle.net/10261/274793
http://hdl.handle.net/10261/274793
Publikováno v:
Cancers, vol. 15, no. 3, pp. 787
Cancers
Volume 15
Issue 3
Pages: 787
Cancers
Volume 15
Issue 3
Pages: 787
Targeting NAD depletion in cancer cells has emerged as an attractive therapeutic strategy for cancer treatment, based on the higher reliance of malignant vs. healthy cells on NAD to sustain their aberrant proliferation and altered metabolism. NAD dep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67380c51d68902d069f8c537181bbd0e
https://doi.org/10.3390/cancers15030787
https://doi.org/10.3390/cancers15030787
Autor:
Anne-Julie Cloux, Maxime Pellegrin, Karima Bouzourene, Michel A. Duchosal, Christian Widmann, Dominique Aubry, Mathieu Heulot, Michele Cea, Francesco Piacente, Alessio Nencioni, Lucia Mazzolai, Oussama ElMokh, Aimable Nahimana, Axel Bellotti
Publikováno v:
Oncotarget, vol. 10, no. 62, pp. 6723-6738
Oncotarget
Oncotarget
APO866 is a small molecule drug that specifically inhibits nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme involved in nicotinamide adenine dinucleotide (NAD) biosynthesis from the natural precursor nicotinamide. Although, the antitumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc4b40cb67b871dadb3d898ba333de97
https://serval.unil.ch/resource/serval:BIB_1BDC3B2158B7.P001/REF.pdf
https://serval.unil.ch/resource/serval:BIB_1BDC3B2158B7.P001/REF.pdf
Autor:
Gertraud Orend, Axel Bellotti, Carola Ries, Stefan Bissinger, Ece Kadioglu, Ioanna Keklikoglou, Benoit Langlois, Michele De Palma
Publikováno v:
Cell Reports
Cell Reports, 2018, 22 (10), pp.2530-2540. ⟨10.1016/j.celrep.2018.02.035⟩
Cell Reports, Vol 22, Iss 10, Pp 2530-2540 (2018)
Cell Reports, Elsevier Inc, 2018, 22 (10), pp.2530-2540
Cell Reports, 2018, 22 (10), pp.2530-2540. ⟨10.1016/j.celrep.2018.02.035⟩
Cell Reports, Vol 22, Iss 10, Pp 2530-2540 (2018)
Cell Reports, Elsevier Inc, 2018, 22 (10), pp.2530-2540
Summary: Resistance to antiangiogenic drugs limits their applicability in cancer therapy. Here, we show that revascularization and progression of pancreatic neuroendocrine tumors (PNETs) under extended vascular-endothelial growth factor A (VEGFA) blo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f825b5d734bed07f5bdb092b9dd86458
https://hal.univ-reims.fr/hal-02185254/document
https://hal.univ-reims.fr/hal-02185254/document
Autor:
Oussama ElMokh, Saki Matsumoto, Paulina Biniecka, Axel Bellotti, Karin Schaeuble, Francesco Piacente, Hector Gallart-Ayala, Julijana Ivanisevic, Ivan Stamenkovic, Alessio Nencioni, Aimable Nahimana, Michel A. Duchosal
Publikováno v:
Cell Death Dis
Cell death & disease, vol. 13, no. 4, pp. 320
Cell death & disease, vol. 13, no. 4, pp. 320
Most cancer cells have high need for nicotinamide adenine dinucleotide (NAD+) to sustain their survival. This led to the development of inhibitors of nicotinamide (NAM) phosphoribosyltransferase (NAMPT), the rate-limiting NAD+ biosynthesis enzyme fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ea8b9c672f1eb63358eb880e0d86408